Lupin receives U.S. FDA EIR for Aurangabad facility after inspection

Regulatory product approvalBusiness Updates View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹2038.30

prior close

₹2051.60

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%+1.2% vs market

Pharmaceuticals peers, median of 157sector-0.1%+1.0% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Midcap 150 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.3

15m

-0.8

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.3+1.2-0.1+1.0

Next day

+0.8-0.3+1.1-0.5+1.3

+0.8+0.4+0.4-0.4+1.2

+0.6-0.2+0.8-1.1+1.7

-0.7+0.1-0.7-1.4+0.7

-0.7+0.1-0.8-1.6+0.9

-2.6-1.4-1.2-3.3+0.8

15d

+2.4-1.2+3.7-3.4+5.8

+2.4-1.2+3.6-4.3+6.7

+6.8-2.1+8.9-6.9+13.7

+7.6-2.3+9.9-8.8+16.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin received the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad (CSN) facility, following a product-specific Pre-Approval Inspection conducted September 1 to 5, 2025. The EIR indicates the FDA has closed the inspection satisfactorily. MD Nilesh Gupta called it a sign of the company's commitment to quality and compliance standards.

Likely market impact

Positive for shareholders - EIR clears regulatory uncertainty for the facility and supports continued U.S. product approvals, aiding future U.S. revenue growth.